Pfizer has announced the withdrawal of all lots of Oxbryta, its drug for sickle cell disease, amid concerns about increased complications and fatal events. 

Large companies can save millions of dollars by addressing one common misconception about health insurance plans, according to billionaire entrepreneur Mark Cuban. 

The FDA is reassessing the approval of immune checkpoint inhibitors for treating advanced HER2-negative gastric adenocarcinoma, questioning their broad application regardless of patients' PD-L1 expression levels. 

A recent study from Harvard Medical School introduced TxGNN, an innovative AI tool designed to identify potential drug candidates for over 17,000 rare and neglected diseases. 

Sen. Bernie Sanders highlighted a potential shift in the pricing of Ozempic during a Senate Health, Education, Labor and Pensions Committee hearing Sept. 24, during which three major pharmacy benefit managers said they would increase coverage if Novo Nordisk lowered the drug's list price. 

In the first quarter of 2024, the U.S. recorded a spike in drug shortages and among GoodRx's list of the top 20 most common medications, half are in shortage. 

Here are eight new drug shortages to know, according to databases compiled by the FDA and the American Society of Health-System Pharmacists: 

CMS is expected to announce in early 2025 the list of up to 15 Medicare Part D drugs that will be subject to price negotiations in 2025, with negotiated prices expected to be implemented in 2027. 

GLP-1 manufacturers are now offering significant discounts to entice payers and employers to cover their popular medications, The Wall Street Journal reported Sept. 20.

The FDA approved FluMist, a nasal spray flu vaccine for self-administration, making it the first flu vaccine of its kind available for at home use. 

A phase 3 study has shown that tolebrutinib, a drug being tested in treating non-relapsing secondary progressive multiple sclerosis, slowed the progression of disability in patients. 

Drugmakers will discontinue the sales of a controversial class of fentanyl-based painkillers by the end of September, the FDA confirmed Sept. 16. 

Bionpharma is recalling a batch of pneumonia drug Atovaquone Oral Suspension after it was found to be contaminated with Cohnella bacteria. 

Becker's asked chief pharmacy officers from hospitals and health systems across the U.S. to share the next steps in their technological journey.

A pair of recent studies highlighted two potential new uses for metformin, a Type 2 diabetes drug. One points to the drug possibly helping people living with HIV, and another shows the drug could benefit adults who have long COVID-19. 

A new study suggests that some recently marketed migraine medications may not be more effective than standard painkillers for treating acute migraine episodes.  

The FDA approved Kisqali for patients with stage 2 or 3 breast cancer and who are at high risk of recurrence. 

On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen testified at a Senate committee hearing about the costs for Wegovy and Ozempic.

BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18. 

Starting Oct. 1, a Louisiana law will classify drugs used for abortion — mifepristone and misoprostol — as controlled substances, requiring hospitals to store them in locked cabinets, The Washington Post reported Sept. 17.